Tracy T Batchelor Selected Research

Aftercare (After-Treatment)

1/2022	Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma.
1/2020	Mechanisms and therapeutic implications of hypermutation in gliomas.
1/2020	Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients.
1/2017	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
1/2012	Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.
5/2010	Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tracy T Batchelor Research Topics

Disease

89	Neoplasms (Cancer) 01/2022 - 03/2003
84	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 01/2004
44	Glioma (Gliomas) 01/2022 - 01/2004
18	Lymphoma (Lymphomas) 01/2022 - 03/2003
14	Brain Neoplasms (Brain Tumor) 01/2021 - 04/2009
4	Oligodendroglioma 01/2022 - 03/2005
4	Necrosis 01/2019 - 01/2011
4	Edema (Dropsy) 11/2018 - 01/2007
3	Meningioma (Meningiomas) 01/2022 - 01/2015
3	Breast Neoplasms (Breast Cancer) 01/2020 - 07/2007
3	Neoplasm Metastasis (Metastasis) 01/2019 - 11/2015
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2019 - 01/2012
3	Disease Progression 01/2014 - 06/2010
3	Brain Edema (Cerebral Edema) 01/2013 - 04/2009
2	Neurologic Manifestations (Neurological Manifestations) 10/2022 - 01/2019
2	Nervous System Trauma 10/2022 - 01/2018
2	Astrocytoma (Pilocytic Astrocytoma) 01/2022 - 12/2006
2	Meningeal Carcinomatosis 08/2020 - 01/2020
2	Inflammation (Inflammations) 01/2020 - 01/2019
2	Fatigue 01/2019 - 10/2009
2	Bacterial Infections (Bacterial Infection) 08/2017 - 05/2009
2	Acoustic Neuroma (Acoustic Neurinoma) 09/2010 - 10/2005
2	Hypertension (High Blood Pressure) 10/2009 - 06/2009
2	Pneumonia (Pneumonitis) 05/2009 - 01/2009
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022
1	Ependymoma 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2021
1	Foreign-Body Granuloma (Granuloma, Foreign Body) 01/2021

Drug/Important Bio-Agent (IBA)

32	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 10/2005
25	Temozolomide (Temodar)FDA LinkGeneric 12/2020 - 04/2006
18	Biomarkers (Surrogate Marker)IBA 01/2020 - 06/2007
18	cediranib (AZD2171)IBA 01/2017 - 01/2007
12	Pharmaceutical PreparationsIBA 12/2020 - 01/2007
12	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2017 - 01/2007
11	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2022 - 09/2013
10	Bevacizumab (Avastin)FDA Link 01/2022 - 02/2010
10	Tyrosine Kinase InhibitorsIBA 01/2019 - 01/2007
8	alpha-hydroxyglutarateIBA 01/2022 - 09/2013
7	Biological ProductsIBA 01/2022 - 01/2004
7	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 04/2006
7	Methotrexate (Mexate)FDA LinkGeneric 01/2018 - 02/2003
6	Angiogenesis InhibitorsIBA 01/2022 - 12/2007
5	Protons (Proton)IBA 03/2019 - 06/2011
5	RNA (Ribonucleic Acid)IBA 01/2019 - 11/2014
5	ErbB Receptors (EGF Receptor)IBA 01/2019 - 11/2005
5	Proteins (Proteins, Gene)FDA Link 01/2017 - 03/2005
5	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2013 - 11/2008
4	TIC10 compoundIBA 11/2020 - 01/2017
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2017 - 07/2007
3	Lomustine (CCNU)FDA Link 01/2020 - 09/2013
3	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 12/2017 - 01/2012
3	Busulfan (Busulfex)FDA Link 12/2017 - 01/2012
3	Phosphotransferases (Kinase)IBA 01/2017 - 04/2006
3	EnzymesIBA 09/2016 - 06/2011
3	CytokinesIBA 01/2016 - 05/2009
3	vandetanib (ZD6474)IBA 08/2015 - 09/2010
3	Thalidomide (Thalomid)FDA Link 01/2009 - 07/2007
2	Hydroxyurea (Hydrea)FDA LinkGeneric 12/2020 - 01/2018
2	Dopamine Receptors (Dopamine Receptor)IBA 11/2020 - 01/2019
2	pembrolizumabIBA 08/2020 - 01/2020
2	epidermal growth factor receptor VIIIIBA 01/2020 - 12/2006
2	dacomitinibIBA 01/2020 - 01/2019
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2019 - 01/2019
2	MethyltransferasesIBA 01/2019 - 01/2018
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2019 - 10/2017
2	SteroidsIBA 01/2019 - 06/2010
2	Chimeric Antigen ReceptorsIBA 01/2019 - 01/2018
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 05/2009
2	Nicotinamide PhosphoribosyltransferaseIBA 01/2018 - 12/2015
2	CreatineIBA 01/2017 - 06/2011
2	Coenzymes (Enzyme Cofactors)IBA 01/2017 - 12/2015
2	Choline (Choline Chloride)IBA 01/2017 - 06/2011
2	O(6)-Methylguanine-DNA MethyltransferaseIBA 01/2016 - 04/2007
2	CilengitideIBA 10/2015 - 11/2014
2	Oxygen (Dioxygen)IBA 01/2013 - 06/2011
2	Transaminases (Aminotransferases)IBA 06/2011 - 01/2009
2	Endothelial Growth FactorsIBA 05/2010 - 05/2009
2	CollagenIBA 06/2009 - 05/2009
2	Celecoxib (Celebrex)FDA Link 06/2008 - 07/2007
2	Alkylating AgentsIBA 04/2007 - 04/2006
1	Inositol (Myoinositol)IBA 01/2022
1	LipidsIBA 01/2022
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022
1	tisagenlecleucelIBA 01/2022
1	Agammaglobulinaemia Tyrosine KinaseIBA 12/2021
1	palbociclibIBA 01/2021
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2021
1	HexokinaseIBA 12/2020

Therapy/Procedure

67	Therapeutics 10/2022 - 03/2003
28	Drug Therapy (Chemotherapy) 12/2020 - 01/2005
27	Radiotherapy 03/2019 - 03/2005
6	Aftercare (After-Treatment) 01/2022 - 05/2010
5	Immunotherapy 01/2019 - 05/2009
3	Salvage Therapy 01/2020 - 03/2005
3	Stem Cell Transplantation 12/2017 - 01/2012
2	Transplantation 01/2019 - 08/2017
2	Precision Medicine 01/2018 - 04/2016
2	Cranial Irradiation 01/2018 - 08/2015
2	Craniotomy 01/2016 - 05/2009
1	Neurosurgical Procedures 01/2021